-
公开(公告)号：US08685725B2
公开(公告)日：2014-04-01
申请号：US13077644
申请日：2011-03-31
申请人： Roland Beliard , Dominique Bourel , Arnaud Glacet , Christophe De Romeuf , Nicolas Bihoreau , Emmanuel Nony
发明人： Roland Beliard , Dominique Bourel , Arnaud Glacet , Christophe De Romeuf , Nicolas Bihoreau , Emmanuel Nony
CPC分类号： C07K16/34 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/41 , C07K2317/52 , C07K2317/732
摘要： The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP.
摘要翻译： 本发明涉及通过ADDC型测试获得和选择单克隆抗体的方法，所述抗体能够激活III型Fcy受体并具有特定的聚糖结构。 本发明的抗-D抗体可用于预防Rh阴性人中的恒河猴同种免疫，特别是用于新生儿如特发性血小板减少性蛹9ITP的新生婴儿中的溶血性疾病。
-
公开(公告)号：US08404241B2
公开(公告)日：2013-03-26
申请号：US13203317
申请日：2010-03-05
IPC分类号： A61K39/395
CPC分类号： C07K16/34 , A61K39/39591 , C07K2317/567
摘要： The invention relates to an anti-RhD monoclonal antibody, which is a tetrameric IgG1 immunoglobulin composed of two heavy chains and two light chains, the heavy chain comprising the amino acid sequence SEQ ID No. 2, harboring a phenylalanine residue at position 68, and the light chain comprising the amino acid sequence SEQ ID No. 4.
摘要翻译： 本发明涉及一种抗RhD单克隆抗体，其是由两条重链和两条轻链组成的四聚体IgG1免疫球蛋白，该重链包含在位置68处含有苯丙氨酸残基的氨基酸序列SEQ ID No.2，以及 所述轻链包含氨基酸序列SEQ ID No.4。
-
公开(公告)号：US20120259095A1
公开(公告)日：2012-10-11
申请号：US13436114
申请日：2012-03-30
申请人： Roland Beliard , Dominique Bourel , Arnaud Glacet , Christophe de Romeuf , Nicolas Bihoreau , Emmanuel Nony
发明人： Roland Beliard , Dominique Bourel , Arnaud Glacet , Christophe de Romeuf , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： C07K16/34
CPC分类号： C07K16/34 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/41 , C07K2317/52 , C07K2317/732
摘要： The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP)
摘要翻译： 本发明涉及通过ADDC型测试获得和选择单克隆抗体的方法，所述抗体能够激活III型Fcy受体并具有特定的聚糖结构。 本发明的抗-D抗体可用于预防Rh阴性人中的恒河猴同种免疫，特别是用于新生婴儿如特发性血小板减少性小蛹9ITP的溶血性疾病）
-
公开(公告)号：US20120258096A1
公开(公告)日：2012-10-11
申请号：US13443532
申请日：2012-04-10
申请人： Roland Beliard , Dominique Bourel , Arnaud Glacet , Christophe de Romeuf , Nicolas Bihoreau , Emmanuel Nony
发明人： Roland Beliard , Dominique Bourel , Arnaud Glacet , Christophe de Romeuf , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/34 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/41 , C07K2317/52 , C07K2317/732
摘要： The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
摘要翻译： 本发明涉及通过ADDC型测试获得和选择单克隆抗体的方法，所述抗体能够激活III型Fcγ受体并具有特定的聚糖结构。 本发明的抗D抗体可用于预防Rh阴性人中的恒河猴异免疫，特别是新生婴儿中的溶血性疾病或特发性血小板减少性紫癜（ITP）等用途。
-
公开(公告)号：US07931895B2
公开(公告)日：2011-04-26
申请号：US11039877
申请日：2005-01-24
申请人： Roland Beliard , Arnaud Glacet , Dominique Bourel , Christophe De Romeuf , Nicolas Bihoreau , Emmanuel Nony
发明人： Roland Beliard , Arnaud Glacet , Dominique Bourel , Christophe De Romeuf , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： A61K39/395 , C12N5/02
CPC分类号： C07K16/34 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/41 , C07K2317/52 , C07K2317/732
摘要： The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP).
摘要翻译： 本发明涉及通过ADDC型测试获得和选择单克隆抗体的方法，所述抗体能够激活III型Fcy受体并具有特定的聚糖结构。 本发明的抗-D抗体可用于预防Rh阴性人中的恒河猴同种免疫，特别是用于新生儿例如特发性血小板减少性小蛹9ITP的新生婴儿中的溶血性疾病。
-
16.发明授权公开(公告)号：US07713524B2
公开(公告)日：2010-05-11
申请号：US10566358
申请日：2004-07-30
申请人： Dominique Bourel , Sylvie Jorieux , Christophe De Romeuf , Philippe Klein , Christine Gaucher , Nicolas Bihoreau , Emmanuel Nony
发明人： Dominique Bourel , Sylvie Jorieux , Christophe De Romeuf , Philippe Klein , Christine Gaucher , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/34 , A61K2039/505 , C07K16/18 , C07K16/2833 , C07K2317/14 , C07K2317/41 , C07K2317/732 , Y02A50/412
摘要： The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
摘要翻译： 本发明涉及在所选细胞系中产生的人或人源化嵌合单克隆抗体的用途，所述抗体导致高ADCC活性以及细胞因子和白细胞介素的高分泌，用于治疗所谓的弱反应患者的人群 显示CD16 FCGR3A-158F纯合子或FCGR3A-158V / F杂合子多态性。
-
17.发明申请TREATMENT OF PATHOLOGIES WHICH ESCAPE THE IMMUNE RESPONSE, USING OPTIMIZED ANTIBODIES 审中-公开使用优化抗体治疗免疫应答的病理学治疗公开(公告)号：US20090081216A1
公开(公告)日：2009-03-26
申请号：US12234609
申请日：2008-09-19
IPC分类号： A61K39/395
CPC分类号： C07K16/2833 , C07K16/2896 , C07K16/34 , C07K2317/732
摘要： The invention relates to the use of potimised human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies having a strong affvinity for receptor CD16 of the effector cells of the immune system and being able to induce the secretion of cytokines and interleukins, in particular 1“IFN? Or 1” IL2, for the treatment of pathologies for which the target cells only express a low antigenic density and in which the effector cells can only be recruited in small quantities.
摘要翻译： 本发明涉及在所选择的细胞系中产生的人体或人源化嵌合单克隆抗体的用途，所述抗体对免疫系统的效应细胞的受体CD16具有很强的亲和性，并能够诱导细胞因子和白介素的分泌 ，特别是1“IFNα或1”IL2，用于治疗目标细胞仅表达低抗原密度并且其中仅能够少量招募效应细胞的病理学。
-
公开(公告)号：US20060182741A1
公开(公告)日：2006-08-17
申请号：US10566358
申请日：2004-07-30
申请人： Dominique Bourel , Sylvie Jorieux , Christophe De Romeuf , Philippe Klein , Christine Gaucher , Nicolas Bihoreau , Emmanuel Nony
发明人： Dominique Bourel , Sylvie Jorieux , Christophe De Romeuf , Philippe Klein , Christine Gaucher , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： A61K39/395 , C07K16/44
CPC分类号： C07K16/34 , A61K2039/505 , C07K16/18 , C07K16/2833 , C07K2317/14 , C07K2317/41 , C07K2317/732 , Y02A50/412
摘要： The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
摘要翻译： 本发明涉及在所选细胞系中产生的人或人源化嵌合单克隆抗体的用途，所述抗体导致高ADCC活性以及细胞因子和白细胞介素的高分泌，用于治疗所谓的弱反应患者的人群 显示CD16 FCGR3A-158F纯合子或FCGR3A-158V / F杂合子多态性。
-
公开(公告)号：US09234045B2
公开(公告)日：2016-01-12
申请号：US11793138
申请日：2005-12-14
CPC分类号： C07K16/2887 , A61K51/1069 , A61K2039/505 , A61P35/02 , A61P37/00 , C07K16/2896 , C07K16/3061 , C07K2317/24 , C07K2317/56 , C07K2317/76 , C12N2510/02
摘要： The invention is directed to a monoclonal antibody directed against CD20 antigen, for therapeutic administration to humans, wherein each of the light chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 27, and each of the heavy chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 19. The invention is further directed to methods of in vitro activation of FcγRIIIA receptors in immune effector cells with the antibody and methods of treating CD20-expressing leukaemia or lymphoma with the antibody.
摘要翻译： 本发明涉及针对CD20抗原的单克隆抗体，用于对人的治疗性施用，其中抗体的每个轻链由鼠 - 人嵌合核酸序列SEQ ID No 27编码，并且每个重链 抗体的编码由SEQ ID No.19的鼠 - 人嵌合核酸序列编码。本发明还涉及用抗体体外激活免疫效应细胞中的FcγRIIIA受体的方法和治疗表达CD20的白血病或淋巴瘤的方法 与抗体。
-
公开(公告)号：US08409572B2
公开(公告)日：2013-04-02
申请号：US13436114
申请日：2012-03-30
申请人： Roland Beliard , Dominique Bourel , Arnaud Glacet , Christophe De Romeuf , Nicolas Bihoreau , Emmanuel Nony
发明人： Roland Beliard , Dominique Bourel , Arnaud Glacet , Christophe De Romeuf , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： A61K39/395 , C07K16/00 , C12P21/08 , C07K1/00
CPC分类号： C07K16/34 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/41 , C07K2317/52 , C07K2317/732
摘要： The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic purpura (ITP).
摘要翻译： 本发明涉及通过ADDC型测试获得和选择单克隆抗体的方法，所述抗体能够激活III型Fcy受体并具有特定的聚糖结构。 本发明的抗-D抗体可用于预防Rh阴性人中的恒河猴同种免疫，特别是用于新生儿例如特发性血小板减少性紫癜（ITP）的新生婴儿中的溶血性疾病。
-
-
-
-
-
-
-
-
-
搜索结果
40 条记录 (耗时 0.034 秒)
